According to GlobalData’s medical device pipeline database, 413 Indication Specific Mobile Apps devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 354 are in active development, while the remaining 67 are in an inactive stage of development. There are 145 products in the early stages of development, and the remaining 209 are in the late stages of development.
Indication Specific Mobile Apps are made to track precise health metrics that are extremely specific for a given disease even outside of clinical settings. Indication Specific Apps include Cancer Apps, Depression Apps, IBS (Irritable Bowel Syndrome) Apps, Obesity Apps, Type 1 Diabetes Apps and Type 2 Diabetes Apps.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Indication Specific Mobile Apps pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Indication Specific Mobile Apps devices. Overall, most of these Indication Specific Mobile Apps pipeline devices are being developed by private entities.
Key players involved in the active development of Indication Specific Mobile Apps include Ad Scientiam, AliveCor, ResApp Health, Precordior, Therma Bright, University of Washington, Treatment Technologies & Insights, University of California San Francisco, BeCare Link and University of Melbourne.
For a complete picture of the developmental pipeline for Indication Specific Mobile Apps devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
